bioRxivCancer BiologyPreprint
CAMKV Kinase Signaling Is a Novel Therapeutic Avenue with Prognostic Relevance in Neuroblastoma
Y. Yu, Y. Zhao, Z. Shi, F. Cheng, L. L. Wang, J. M. Choi, K. Li, D. Silverman, D. Qi, J. Wang, S. Agarwal, B. Rood, J. S. Dome, M. Fabbri, J. S. Yi, E. Wu, S. Y. Jung, C. Zhang, J. Yang
Abstract
Neuroblastoma (NB) can be a highly aggressive malignancy in children. However, the precise mechanisms driving NB tumorigenesis remain elusive. This study revealed the critical role of CREB phosphorylation in NB cell proliferation. By employing a CRISPR-Cas9 knockout screen targeting calcium/calmodulin-dependent protein kinase (CaMK) family members, we identified the CaM kinase-like vesicle-associated (CAMKV) protein as a kinase that mediates direct phosphorylation of CREB to promote NB cell proliferation. CAMKV was found to be a transcriptional target of MYCN/MYC in NB cells. CAMKV knockout and knockdown effectively suppressed NB cell proliferation and tumor growth both in vitro and in vivo. Bioinformatic analysis revealed that high CAMKV expression is significantly correlated with poor patient survival. High-risk NB frequently had high CAMKV protein levels by Immunohistochemical staining. Integrated transcriptomic and proteomic analyses of CAMKV knockdown cells unveiled downstream targets involved in CAMKV-regulated phosphorylation and signaling pathways, many of which are linked to neural development and cancer progression. We identified small molecule inhibitors targeting CAMKV and further demonstrated the efficacy of one inhibitor in suppressing NB tumor growth and prolonging the survival of mice bearing xenografted tumors. These findings reveal a critical role for CAMKV kinase signaling in NB growth and identified CAMKV kinase as a potential therapeutic target and prognostic marker for patients with NB.
- organism: human
- assay: proteomics
- assay: bulk RNA-seq
- research focus: cell signaling & trafficking
- research focus: drug response / drug discovery
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A novel druggable DYRK3/CAMKV signaling module for Neuroblastoma tumor growth inhibition.
E. J. Rozen, K. Wigglesworth, J. M. Shohet·bioRxiv·Nov 30, 2023
- Phosphorylation of MYCN and MAX by PAK family kinases is a novel tumor-suppressor mechanism in neuroblastoma with potential therapeutic implications.
E. J. Rozen, K. Wigglesworth, J. M. Shohet·bioRxiv·Dec 4, 2023
- MYCN inhibits TrkC-mediated differentiation in neuroblastoma cells via disruption of the PKA signalling pathway
Stephanie Maher, Andrew Roe, … Melinda Halász·Cell Death DiscoveryPeer-reviewed·Mar 25, 2026
- KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma
- Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy
L. Grunewald, L. Andersch, … A. Kuenkele·bioRxiv·Jan 27, 2024
- Ribosome biogenesis is a therapeutic vulnerability in paediatric neuroblastoma
Camille Jouines, Piero Lo Monaco, … Frédéric Catez·bioRxiv·Mar 26, 2025